Bakteriyofaj Terapisinin Enfeksiyonların Tedavisinde Dünü Bugünü Yarını

Sulakvelidze A, Alavidze Z, Morris JG, Jr. Bacteriophage therapy. Antimicrobial Agents and Chemotherapy. 2001;45(3):649-59. doi:10.1128/AAC.45.3.649-659.2001

Mustafa A. Bakteriyofajlar (Bakteriyel Viruslar). Temel Mikrobiyoloji. Ankara: Medisan Yayınevi; 2011. p. 182-94

https://docplayer.biz.tr/40786538-Bakteriyofaj-enkapsulasyonu-ve-potansiyel-uygulamalari.html [

Gündoğdu A U-KA. Bacteriophage Therapy: An Unforgetten Source of Cure. Klimik Journal. 2018;31(2). doi:10.5152/kd.2018.22

Cold F, Olsen NS, Djurhuus A, et al. [Bacteriophage therapy]. Ugeskr Laeger. 2020;182(27)

Kortright KE, Chan BK, Koff JL, et al. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host Microbe. 2019;25(2):219-32. doi:10.1016/j.chom.2019.01.014

Saygılı D, Karagözlü C. Bakteriyofaj Enkapsülasyonu ve Potansiyel Uygulamaları. Gıda Dergisi. 2017;42(1):58-66. doi: 10.15237/gida.GD16055

Feiner R, Argov T, Rabinovich L, et al. A new perspective on lysogeny: prophages as active regulatory switches of bacteria. Nature Reviews Microbiology. 2015;13(10):641-50. doi: 10.1038/nrmicro3527.

Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends in biotechnology. 2010;28(12):591-5. doi: 10.1016/j.tibtech.2010.08.001.

D'Herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. 1917. Research in Microbiology 2007;158(7):553-4. doi:10.1016/j.resmic.2007.07.005

d'Herelle F, Smith GH. The bacteriophage and its behavior: Nature; 1926. doi:10.1038/118183a0

Summers W. Plague and cholera in India: the bacteriophage inquiry of 1928–1936. Journal of the History of Medicine and Allied Sciences. 1993;48(3):275-301. doi:10.1093/jhmas/48.3.275

d'Herelle F, Malone RH, Lahiri MN. Studies on Asiatic cholera. Studies on Asiatic Cholera. 1930(Memoir No. 14)

Hadley P. The Twort-D'Herelle phenomenon: a critical review and presentation of a new conception (homogamic theory) of bacteriophage action. The Journal of Infectious Diseases. 1928;42(4):263-434. doi:10.1093/infdis/42.4.263

Smith J. The Bacteriophage in the Treatment of Typhoid Fever. British Medical Journal. 1924;2(3315):47-9. doi:10.1136/bmj.2.3315.47

Ho K. Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotics era. Perspectives in Biology and Medicine. 2001;44(1):1-16. doi:10.1353/pbm.2001.0006

Cowie D, Hicks W. Observations on the bacteriophage III. Journal of Laboratory and Clinical Medicine 1932;17:685

Krestownikowa W, Gubin W. Die Verteilung and die Ausscheidung von Bak-teriophagen im Meerschweinchen-organismus bei subkutaner Applicationsart. J Microbiol, Patolog i Infekzionnich bolesney. 1925;1(3)

Luria SE, Delbruck M. Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics. 1943;28(6):491-511. doi:10.1093/genetics/28.6.491

Riding D. Acute Bacillary Dysentery in Khartoum Province, Sudan, with Special Reference to Bacteriophage Treatment: Bacteriological Investigation. The Journal of Hygiene (London). 1930;30(3):387-401. doi:10.1017/s0022172400010512

Eaton MD, Bayne-Jones S. Bacteriophage therapy: review of the principles and results of the use of bacteriophage in the treatment of infections. Journal of the American Medical Association. 1934;103(23):1769-76. doi:10.1001/jama.1934.72750490003007

Krueger AP, Scribner EJ. The bacteriophage: its nature and its therapeutic use. Journal of the American Medical Association. 1941;116(20):2269-77. doi:10.1001/jama.1941.62820190016010

Summers WC. Bacteriophage therapy. Annual Review of Microbiology. 2001;55:437-51.doi:10.1146/annurev.micro.55.1.437

Wittig HJ, Raffetto JF, Bason R. Bacteriophage therapy in infective childhood asthma. Journal of the American Medical Association. 1966;196(5):435

Monsur KA, Rahman MA, Huq F, et al. Effect of massive doses of bacteriophage on excretion of vibrios, duration of diarrhoea and output of stools in acute cases of cholera. Bulletin of the World Health Organization. 1970;42(5):723-32

Fleming A. Penicillin’s finder assays its future. New York Times. 1945;26:21

Marshall G, Blacklock J, Cameron C, et al. Streptomycin treatment of pulmonary tuberculosis: a medical research council investigation. British Medical Journal. 1948;2(4582):769-82

Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2008;46(2):155-64. doi:10.1086/524891

Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535):455-9. doi: 10.1038/nature14098.

Hover BM, Kim S-H, Katz M, et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nature microbiology. 2018;3(4):415-22. doi: 10.1038/s41564-018-0110-1.

Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspectives in Medicinal Chemistry. 2014;6:25-64. doi:10.4137/PMC.S14459

Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases. 2018;18(3):318-27. doi:10.1016/S1473-3099(17)30753-3

O’Neil J. Review on Antibiotic resistance. 2014.

de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS medicine. 2016;13(11):e1002184. doi: 10.1371/journal.pmed.1002184.

Bassetti M, Poulakou G, Ruppe E, et al. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Medicine. 2017;43(10):1464-75. doi:10.1007/s00134-017-4878-x

Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. Journal of Infection in Developing Countries. 2014;8(2):129-36. doi:10.3855/jidc.3573

Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. Journal of General Microbiology. 1982;128(2):307-18. doi:10.1099/00221287-128-2-307

Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. Journal of General Microbiology. 1983;129(8):2659-75. doi:10.1099/00221287-129-8-2659

Merril CR, Biswas B, Carlton R, et al. Long-circulating bacteriophage as antibacterial agents. Proceedings of the National Academy of Sciences. 1996;93(8):3188-92. doi: 10.1073/pnas.93.8.3188.

Soothill JS. Treatment of experimental infections of mice with bacteriophages. Journal of Medical Microbiology. 1992;37(4):258-61. doi:10.1099/00222615-37-4-258

Letkiewicz S, Miedzybrodzki R, Klak M, et al. The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunology and Medical Microbiology. 2010;60(2):99-112. doi:10.1111/j.1574-695X.2010.00723.x

Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: treatment of human infections. Current Pharmaceutical Biotechnology. 2010;11(1):69-86. doi:10.2174/138920110790725401

Slopek S, Weber-Dabrowska B, Dabrowski M, et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Archivum Immunologiae et Therapiae Experimentalis (Warsz). 1987;35(5):569-83

Markoishvili K, Tsitlanadze G, Katsarava R, et al. A novel sustained‐release matrix based on biodegradable poly (ester amide) s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. International Journal of Dermatology. 2002;41(7):453-8. doi: 10.1046/j.1365-4362.2002.01451.x.

Henein A. What are the limitations on the wider therapeutic use of phage? Bacteriophage. 2013;3(2):e24872. doi: 10.4161/bact.24872.

Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage therapy. Current Pharmaceutical Biotechnology 2010;11(1):2-14. doi:10.2174/138920110790725311

Pirnay J-P, Merabishvili M, Raemdonck HV, et al. Bacteriophage production in compliance with regulatory requirements. Bacteriophage therapy;doi: 10.1007/978-1-4939-7395-8_18: Springer; 2018. p. 233-52. doi: 10.1007/978-1-4939-7395-8_18

Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111-4. doi:10.4161/bact.1.2.14590

Abedon ST. Bacteriophage clinical use as antibacterial “drugs”: utility and precedent. Microbiology Spectrum. 2017;5(4):5.4.16. doi: 10.1128/microbiolspec.BAD-0003-2016

Speck P, Smithyman A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiology Letters. 2016;363(3). doi:10.1093/femsle/fnv242

Roach DR, Debarbieux L. Phage therapy: awakening a sleeping giant. Emerging Topics in Life Sciences. 2017;1(1):93-103. doi:10.1042/ETLS20170002

Lusiak-Szelachowska M, Zaczek M, Weber-Dabrowska B, et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunology. 2014;27(6):295-304. doi:10.1089/vim.2013.0128

Hodyra-Stefaniak K, Miernikiewicz P, Drapala J, et al. Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Scientific Reports. 2015;5(1):14802. doi:10.1038/srep14802

Weber-Dabrowska B, Zimecki M, Mulczyk M, et al. Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunology and Medical Microbiology 2002;34(2):135-8. doi:10.1111/j.1574-695X.2002.tb00614.x

Jonczyk-Matysiak E, Lusiak-Szelachowska M, Klak M, et al. The Effect of Bacteriophage Preparations on Intracellular Killing of Bacteria by Phagocytes. Journal of Immunology Research. 2015;2015:482863. doi:10.1155/2015/482863

Przerwa A, Zimecki M, Switala-Jelen K, et al. Effects of bacteriophages on free radical production and phagocytic functions. Medical Microbiology and Immunology. 2006;195(3):143-50. doi:10.1007/s00430-006-0011-4

Meladze G, Mebuke M, Chkhetia SN. The efficacy of staphylococcal bacteriophage in the treatment of purulent diseases of the lungs and pleura. Grudnaia Khirurgiia (Moscow, Russia). 1982(1):53-6

Kochetkova VA, Mamontov AS, Moskovtseva RL, et al. [Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms]. Sov Med. 1989(6):23-6

Sakandelidze VM. [The combined use of specific phages and antibiotics in different infectious allergoses]. Vrachebnoe Delo. 1991(3):60-3

Shariati A, Azimi T, Ardebili A, et al. Insertional inactivation of oprD in carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Tehran, Iran. New Microbes and New Infections 2018;21:75-80. doi:10.1016/j.nmni.2017.10.013

Mah TF, Pitts B, Pellock B, et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature. 2003;426(6964):306-10. doi:10.1038/nature02122

Bahramian A, Khoshnood S, Shariati A, et al. Molecular characterization of the pilS2 gene and its association with the frequency of Pseudomonas aeruginosa plasmid pKLC102 and PAPI-1 pathogenicity island. Infection and Drug Resistance. 2019;12:221-7. doi:10.2147/IDR.S188527

Remold SK, Brown CK, Farris JE, et al. Differential habitat use and niche partitioning by Pseudomonas species in human homes. Microbial Ecology. 2011;62(3):505-17. doi:10.1007/s00248-011-9844-5

Wagner VE, Filiatrault MJ, Picardo KF, et al. Pseudomonas aeruginosa virulence and pathogenesis issues. Pseudomonas genomics and molecular biology 2008. p. 129-158

Breidenstein EB, de la Fuente-Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends in microbiology. 2011;19(8):419-26. doi: 10.1016/j.tim.2011.04.005.

Eurosurveillance editorial team C. CDC publishes report on antibiotic resistance threats in the United States for the first time. European Centre for Disease Prevention and Control (ECDC); 2013

Pires DP, Vilas Boas D, Sillankorva S, et al. Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections. Journal of Virology. 2015;89(15):7449-56. doi:10.1128/JVI.00385-15

Kellenberger G, Kellenberger E. Electron microscopical studies of phage multiplication. III. Observation of single cell bursts. Virology. 1957;3(2):275-85. doi:10.1016/0042-6822(57)90093-4

Holloway BW, Egan JB, Monk M. Lysogeny in Pseudomonas aeruginosa. The Australian Journal of Experimental Biology and Medical Science. 1960;38(4):321-9. doi:10.1038/icb.1960.34

Gu J, Liu X, Li Y, et al. A method for generation phage cocktail with great therapeutic potential. PLoS One. 2012;7(3):e31698. doi:10.1371/journal.pone.0031698

Jaiswal A, Koley H, Ghosh A, et al. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes and Infection 2013;15(2):152-6. doi:10.1016/j.micinf.2012.11.002

Hall AR, De Vos D, Friman VP, et al. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Applied and Environmental Microbiology. 2012;78(16):5646-52. doi:10.1128/AEM.00757-12

Fong SA, Drilling A, Morales S, et al. Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients. Frontiers in Cellular and Infection Microbiology 2017;7:418. doi:10.3389/fcimb.2017.00418

Wang J, Hu B, Xu M, et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. International Journal of Molecular Medicine. 2006;17(2):309-17

Oechslin F, Piccardi P, Mancini S, et al. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. The Journal of infectious diseases. 2017;215(5):703-12. doi: 10.1093/infdis/jiw632.

Duplessis C, Biswas B, Hanisch B, et al. Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy. Journal of the Pediatric Infectious Diseases Society. 2018;7(3):253-6. doi:10.1093/jpids/pix056

Khawaldeh A, Morales S, Dillon B, et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. Journal of Medical

Microbiology.2011;60(Pt11):1697-700. doi:10.1099/jmm.0.029744-0

Wright A, Hawkins C, Änggård E, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic‐resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clinical otolaryngology. 2009;34(4):349-57. doi: 10.1111/j.1749-4486.2009.01973.x.

Rossitto M, Fiscarelli EV, Rosati P. Challenges and promises for planning future clinical research into bacteriophage therapy against Pseudomonas aeruginosa in cystic fibrosis. An argumentative review. Frontiers in Microbiology. 2018;9:775. doi: 10.3389/fmicb.2018.00775.

McConnell MJ, Actis L, Pachon J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiology Reviews. 2013;37(2):130-55. doi:10.1111/j.1574-6976.2012.00344.x

İnce N, GEYİK MF, ÖZDEMİR D, et al. Hastane İnfeksiyonu Etkeni Olan Pseudomonas Aerugınosa Suşlarının Yıllara Göre Antibiyotik Duyarlılıklarının Karşılaştırılması. Ankem Dergisi. 2014;28(3):94-9. doi:10.5222/ankem.2014.094

Uğur M, Genç S. Yoğun Bakım Ünitelerinden İzole Edilen Acinetobacter baumannii ve Pseudomonas aeruginosa Suşlarının Üç Yıllık Direnç Profili. Turkish Journal of Intensive Care. 2019;17(3):130-7. doi: 10.4274/tybd.galenos.2018.94103

Hua Y, Luo T, Yang Y, et al. Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant Acinetobacter baumannii in mice. Frontiers in Microbiology. 2018;8:2659. doi: 10.3389/fmicb.2017.02659.

Kusradze I, Karumidze N, Rigvava S, et al. Characterization and testing the efficiency of Acinetobacter baumannii phage vB-GEC_Ab-M-G7 as an antibacterial agent. Frontiers in Microbiology. 2016;7:1590. doi: 10.3389/fmicb.2016.01590.

Cha K, Oh HK, Jang JY, et al. Characterization of two novel bacteriophages infecting multidrug-resistant (MDR) Acinetobacter baumannii and evaluation of their therapeutic efficacy in vivo. Frontiers in Microbiology. 2018;9:696. doi: 10.3389/fmicb.2018.00696.

Schooley RT, Biswas B, Gill JJ, et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrobial Agents and Chemotherapy. 2017;61(10):e00954-17. doi:10.1128/AAC.00954-17

LaVergne S, Hamilton T, Biswas B, et al. Acinetobacter baumannii Phage Therapy for a Multidrug-Resistant Craniectomy Site Infection. Open Forum Infectious Diseases. 2018;5(4):ofy064. doi: 10.1093/ofid/ofy064.

Furfaro LL, Payne MS, Chang BJ. Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles. Frontiers in Cellular and Infection Microbiology. 2018;8:376. doi:10.3389/fcimb.2018.00376

Edgar B. The genome of bacteriophage T4: an archeological dig. Genetics. 2004;168(2):575-82. doi:10.1093/genetics/168.2.575

Cabal A, Garcia-Castillo M, Canton R, et al. Prevalence of Escherichia coli Virulence Genes in Patients with Diarrhea and a Subpopulation of Healthy Volunteers in Madrid, Spain. Frontiers in Microbiology. 2016;7:641. doi:10.3389/fmicb.2016.00641

Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Medicine. 2016;8(1):39. doi:10.1186/s13073-016-0294-z

Brussow H, Canchaya C, Hardt WD. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiology and Molecular Biology Reviews. 2004;68(3):560-602, table of contents. doi:10.1128/MMBR.68.3.560-602.2004

Tomat D, Migliore L, Aquili V, et al. Phage biocontrol of enteropathogenic and shiga toxin-producing Escherichia coli in meat products. Frontiers in Cellular and Infection Microbiology. 2013;3:20. doi:10.3389/fcimb.2013.00020

Niu YD, McAllister TA, Nash JH, et al. Four Escherichia coli O157:H7 phages: a new bacteriophage genus and taxonomic classification of T1-like phages. PLoS One. 2014;9(6):e100426. doi:10.1371/journal.pone.0100426

Dufour N, Debarbieux L, Fromentin M, et al. Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages. Critical Care Medicine. 2015;43(6):e190-8. doi:10.1097/CCM.0000000000000968

Dufour N, Clermont O, La Combe B, et al. Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex. Journal of Antimicrobial Chemotherapy. 2016;71(11):3072-80. doi:10.1093/jac/dkw253

Barrow P, Lovell M, Berchieri A, Jr. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clinical and Diagnostic Laboratory Immunology. 1998;5(3):294-8. doi:10.1128/CDLI.5.3.294-298.1998

Huff WE, Huff GR, Rath NC, et al. Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poultry Science 2003;82(7):1108-12. doi:10.1093/ps/82.7.1108

Cao F, Wang X, Wang L, et al. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. BioMed Research International. 2015;2015:752930. doi:10.1155/2015/752930

Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. Journal of Medical Microbiology. 2011;60(Pt 2):205-10. doi:10.1099/jmm.0.018580-0

Hung CH, Kuo CF, Wang CH, et al. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrobial Agents and Chemotherapy. 2011;55(4):1358-65. doi:10.1128/AAC.01123-10

Bogovazova GG, Voroshilova NN, Bondarenko VM, et al. [Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages]. Zhurnal Mikrobiologii Epidemiologii i Immunobiologii. 1992(3):30-3

Ogston A. Micrococcus poisoning. Journal of anatomy and physiology. 1882;16(Pt 4):526

Skinner D, Keefer CS. Significance of bacteremia caused by Staphylococcus aureus: a study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Archives of internal medicine. 1941;68(5):851-75. doi:10.1001/archinte.1941.00200110003001

Uslan DZ, Crane SJ, Steckelberg JM, et al. Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Archives of internal medicine. 2007;167(8):834-9. doi:10.1001/archinte.167.8.834

Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clinical Infectious Diseases. 2005;41(4):507-14. doi:10.1086/431979

Federspiel JJ, Stearns SC, Peppercorn AF, et al. Increasing US rates of endocarditis with Staphylococcus aureus: 1999-2008. Archives of Internal Medicine. 2012;172(4):363-5. doi:10.1001/archinternmed.2011.1027

Kutateladze á, Adamia R. Phage therapy experience at the Eliava Institute. Médecine et maladies infectieuses. 2008;38(8):426-30. doi: 10.1016/j.medmal.2008.06.023.

Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy for infections in cancer patients. Clinical and Applied Immunology Reviews. 2001;1(3-4):131-4. doi:10.1016/S1529-1049(01)00015-0

Fish R, Kutter E, Wheat G, et al. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. Journal of wound care. 2016;25(Sup7):S27-S33. doi.org/10.12968/jowc.2016.25.Sup7.S27